Breast Surgery — MCQs

Breast Surgery Indian Medical PG Practice Questions and MCQs

Question 11: Which type of breast cancer has the best prognosis?

A. Mucinous carcinoma (Correct Answer)
B. Medullary carcinoma
C. Invasive ductal carcinoma
D. Lobular carcinoma

Explanation: **Explanation:** The prognosis of breast cancer is primarily determined by its histological subtype, grade, and molecular markers. Among the options provided, **Mucinous (Colloid) carcinoma** carries the best prognosis. 1. **Mucinous Carcinoma (Correct):** This is a rare subtype (approx. 2% of cases) characterized by clusters of tumor cells floating in large pools of extracellular mucin. It typically occurs in older women, is slow-growing, and has a very low incidence of axillary lymph node metastasis. When it presents in its "pure" form, the 10-year survival rate exceeds 90%. 2. **Medullary Carcinoma:** While it generally has a better prognosis than standard invasive ductal carcinoma (IDC) due to its well-circumscribed nature and heavy lymphocytic infiltrate, it is still more aggressive than the pure mucinous subtype. It is often associated with BRCA1 mutations. 3. **Invasive Ductal Carcinoma (IDC):** This is the most common type of breast cancer (70-80%). It has a highly variable prognosis but is generally more aggressive than mucinous or medullary types because it lacks the favorable histological features that limit spread. 4. **Lobular Carcinoma:** Invasive lobular carcinoma (ILC) often presents with a "single-file" pattern (Indian file). While its prognosis is similar to IDC, it is frequently multifocal and bilateral, making surgical management more complex. **NEET-PG High-Yield Pearls:** * **Best Prognosis overall:** Tubular carcinoma (often >95% 10-year survival). * **Worst Prognosis:** Inflammatory breast cancer (T4d). * **Molecular Subtype with best prognosis:** Luminal A (ER/PR positive, HER2 negative, low Ki-67). * **Paget’s Disease of the nipple:** Usually associated with an underlying DCIS or invasive carcinoma.

Question 12: Which of the following medications should NOT be given in cyclic mastalgia?

A. Evening primrose oil
B. Danazol
C. Tamoxifen
D. Estrogen (Correct Answer)

Explanation: **Explanation:** **Cyclic mastalgia** is characterized by breast pain that fluctuates with the menstrual cycle, typically peaking during the luteal phase. The underlying pathophysiology is linked to hormonal imbalances, specifically an **excess of estrogen** or a relative deficiency of progesterone, leading to ductal proliferation and interstitial edema. **Why Estrogen is the correct answer:** Since cyclic mastalgia is often exacerbated by high levels of circulating estrogen, administering **Estrogen (Option D)** would worsen the condition rather than treat it. Estrogen promotes breast tissue proliferation and fluid retention, which are the primary drivers of cyclic pain. **Analysis of Incorrect Options:** * **Evening Primrose Oil (Option A):** Contains gamma-linolenic acid (GLA). It is often used as a first-line non-hormonal treatment to restore the balance of essential fatty acids, which may reduce breast sensitivity to hormones. * **Danazol (Option B):** An antigonadotropin that inhibits the pituitary-ovarian axis. It is the only FDA-approved drug for severe mastalgia, though its use is limited by androgenic side effects (weight gain, acne, hirsutism). * **Tamoxifen (Option C):** A Selective Estrogen Receptor Modulator (SERM). It blocks estrogen receptors in the breast and is highly effective for refractory mastalgia, though it is used off-label. **NEET-PG High-Yield Pearls:** 1. **First-line management:** Reassurance and a well-fitted sports bra (effective in 70-80% of cases). 2. **First-line pharmacological agent:** Topical NSAIDs (e.g., Diclofenac gel). 3. **Gold standard for severe cases:** Danazol (but Tamoxifen is often preferred clinically due to a better side-effect profile). 4. **Bromocriptine:** Previously used but now avoided due to significant side effects.

Question 13: Which of the following is an increased risk factor for carcinoma of the breast?

A. BRCA1 mutation (Correct Answer)
B. Breast feeding
C. Multiparity
D. Smoking

Explanation: **Explanation:** The correct answer is **A. BRCA1 mutation**. **1. Why BRCA1 mutation is correct:** BRCA1 (Brest Cancer Gene 1) is a tumor suppressor gene located on chromosome 17q. It plays a critical role in DNA repair via homologous recombination. A germline mutation in this gene leads to genomic instability, significantly increasing the lifetime risk of developing breast cancer (up to 65-80%) and ovarian cancer (up to 40%). It is the most significant genetic risk factor among the options provided. **2. Why the other options are incorrect:** * **B. Breastfeeding:** This is a **protective factor**. Prolonged lactation reduces the total number of ovulatory cycles and promotes the differentiation of mammary epithelial cells, thereby lowering the risk of breast cancer. * **C. Multiparity:** Having multiple children is **protective**. Early first full-term pregnancy (before age 20) and high parity reduce lifetime estrogen exposure. Conversely, *nulliparity* (having no children) is a known risk factor. * **D. Smoking:** While smoking is a major risk factor for many malignancies (like lung and bladder cancer), its direct association with breast cancer is less definitive compared to hormonal and genetic factors. In the context of NEET-PG, it is generally considered a "weak" or inconsistent risk factor compared to a high-penetrance mutation like BRCA1. **High-Yield Clinical Pearls for NEET-PG:** * **BRCA1 vs. BRCA2:** BRCA1 is on Chromosome **17**; BRCA2 is on Chromosome **13**. * **Male Breast Cancer:** More strongly associated with **BRCA2** mutations than BRCA1. * **Triple Negative Breast Cancer (TNBC):** BRCA1 mutations are frequently associated with the basal-like (TNBC) subtype. * **Other Risk Factors:** Early menarche (<12 years), late menopause (>55 years), HRT use, and atypical ductal hyperplasia (ADH).

Question 14: Which of the following statements is false regarding fibroadenoma?

A. It is a benign tumor.
B. It is typically painless.
C. It commonly occurs in young females.
D. It is not encapsulated. (Correct Answer)

Explanation: ### Explanation **Fibroadenoma** is the most common benign tumor of the female breast, often referred to as the **"Breast Mouse"** due to its high mobility within the breast tissue. #### 1. Why Option D is the Correct (False) Statement Fibroadenoma is a **true benign neoplasm** that is **well-encapsulated**. On gross examination, it appears as a firm, lobulated, greyish-white mass with a distinct capsule that allows it to be easily "shelled out" during surgical excision (enucleation). Stating that it is not encapsulated is pathologically incorrect. #### 2. Analysis of Other Options * **Option A (Benign tumor):** This is true. It arises from the terminal duct lobular unit and involves both epithelial and stromal proliferation. It has no malignant potential in its simple form. * **Option B (Typically painless):** This is true. Fibroadenomas usually present as a painless, firm, and discrete lump. Pain is rare unless the tumor undergoes rapid growth (e.g., during pregnancy). * **Option C (Commonly occurs in young females):** This is true. The peak incidence is between **15–35 years** of age. It is considered an aberration of normal development and involution (ANDI). #### 3. NEET-PG High-Yield Clinical Pearls * **Mobility:** Its hallmark is extreme mobility within the breast parenchyma. * **Mammography:** Often shows a well-defined mass; in older women, it may show characteristic **"Popcorn calcification"** (due to involution). * **USG:** Usually shows a hypoechoic, well-circumscribed, oval mass with a horizontal orientation (wider than tall). * **Management:** Conservative management is preferred for small lesions (<3 cm). Surgical **enucleation** is indicated if the lump is large, increasing in size, or if the patient is anxious. * **Giant Fibroadenoma:** Defined as a fibroadenoma >5 cm in diameter or >500g in weight.

Question 15: What is an absolute contraindication for conservative breast cancer therapy?

A. Large pendulous breast
B. History of previous radiation (Correct Answer)
C. Axillary node involvement
D. Subareolar lump present

Explanation: **Explanation:** Breast Conservative Surgery (BCS), which includes wide local excision and mandatory postoperative radiotherapy, is the standard of care for early-stage breast cancer. However, its success depends on the ability to deliver safe radiation and achieve clear margins with acceptable cosmesis. **Why the correct answer is right:** **History of previous radiation** to the breast or chest wall is an **absolute contraindication**. Since BCS must be followed by radiotherapy to reduce the risk of local recurrence, a patient who has already received radiation cannot be re-irradiated due to the risk of cumulative tissue toxicity, skin necrosis, and poor wound healing. **Analysis of incorrect options:** * **Large pendulous breast:** This is a **relative contraindication**. While it may pose technical challenges for radiotherapy planning and cosmesis, it does not strictly prohibit BCS. * **Axillary node involvement:** This is **not a contraindication**. Nodal status determines the need for axillary lymph node dissection or clearance and systemic therapy, but it does not dictate whether the primary breast tumor can be conserved. * **Subareolar lump:** This was previously considered a contraindication, but with modern oncoplastic techniques, it is now a **relative contraindication**. Central tumors can be managed with BCS provided the nipple-areola complex is excised and clear margins are obtained. **High-Yield Clinical Pearls for NEET-PG:** * **Absolute Contraindications for BCS:** 1. Prior radiation to the breast/chest wall. 2. Pregnancy (Radiotherapy is contraindicated; however, BCS may be done in the 3rd trimester if RT is delayed until after delivery). 3. Multicentric disease (tumors in different quadrants). 4. Diffuse malignant-appearing microcalcifications on mammography. 5. Persistent positive margins after re-excision. * **Relative Contraindications:** Active connective tissue diseases (e.g., Scleroderma, SLE) due to poor tolerance of RT, and a high tumor-to-breast ratio.

Question 16: Breast cancer mainly spreads to the vertebrae via:

A. Arterial route
B. Direct invasion
C. Batson's venous plexus (Correct Answer)
D. Axillary lymph nodes

Explanation: **Explanation:** **Correct Answer: C. Batson's venous plexus** The primary route for breast cancer metastasis to the vertebrae is through **Batson’s venous plexus**. This is a valveless, low-pressure network of veins that connects the deep pelvic veins and thoracic veins (including the intercostal veins) to the internal vertebral venous plexus. Because these veins lack valves, changes in intra-abdominal or intra-thoracic pressure (e.g., coughing or straining) can cause retrograde blood flow. This allows malignant cells from the breast to bypass the systemic circulation (cava and lungs) and seed directly into the spinal column and skull. **Analysis of Incorrect Options:** * **A. Arterial route:** While systemic spread can occur via arteries, it is not the primary or characteristic route for the early, localized vertebral metastasis seen in breast cancer. * **B. Direct invasion:** Breast cancer may invade the chest wall (pectoralis muscles), but it does not typically reach the posterior vertebral column through direct tissue extension. * **D. Axillary lymph nodes:** These are the primary site for **lymphatic** spread. While they are crucial for staging and prognosis, they do not provide a direct anatomical pathway to the vertebrae. **High-Yield Clinical Pearls for NEET-PG:** * **Batson’s Plexus** is also the reason why **Prostate Cancer** frequently metastasizes to the lumbar vertebrae. * The most common site of distant metastasis in breast cancer is **Bone** (specifically the spine, pelvis, and ribs). * The most common **organ** for metastasis is the **Lung** (via systemic venous drainage). * **Skip Metastasis:** Occasionally, breast cancer can spread to internal mammary nodes without involving axillary nodes, especially in medial quadrant tumors.

Question 17: Chronic treatment with tamoxifen can cause carcinoma of which organ?

A. Ovary
B. Endometrium (Correct Answer)
C. Cervix
D. Vulva

Explanation: **Explanation:** Tamoxifen is a **Selective Estrogen Receptor Modulator (SERM)**. Its mechanism of action is tissue-specific, acting as an estrogen **antagonist** in the breast but as an estrogen **agonist** in the uterus and bone. **Why Endometrium is correct:** In the postmenopausal uterus, tamoxifen exerts a pro-estrogenic effect on the endometrial lining. This leads to endometrial hyperplasia, polyp formation, and significantly increases the risk of **Endometrial Carcinoma** (specifically endometrioid adenocarcinoma). Patients on long-term tamoxifen therapy must be monitored for any abnormal vaginal bleeding. **Why other options are incorrect:** * **Ovary:** Tamoxifen does not have a significant agonistic effect on the ovarian epithelium. In fact, in premenopausal women, it may cause functional ovarian cysts, but it is not a recognized risk factor for ovarian carcinoma. * **Cervix & Vulva:** The estrogenic stimulatory effect of tamoxifen is specific to the endometrial lining. There is no clinical evidence linking tamoxifen use to an increased incidence of cervical or vulvar malignancies. **High-Yield Clinical Pearls for NEET-PG:** * **Dual Action:** Tamoxifen is the drug of choice for ER-positive breast cancer in both pre- and postmenopausal women. * **Bone Benefit:** Due to its agonistic effect on bone, it helps prevent postmenopausal osteoporosis. * **Lipid Profile:** It decreases LDL levels (beneficial). * **Adverse Effects:** Increased risk of **Thromboembolism** (DVT/PE) and **Cataracts**. * **Alternative:** In postmenopausal women, **Aromatase Inhibitors** (e.g., Anastrozole) are often preferred as they do not increase the risk of endometrial cancer.

Question 18: Which of the following statements about DCIS of the breast is true?

A. DCIS is a benign proliferation of epithelial cells.
B. DCIS involves only specific sectors of the breast.
C. DCIS is almost always detected histologically.
D. Rarely, DCIS can produce nipple discharge. (Correct Answer)

Explanation: **Ductal Carcinoma in Situ (DCIS)** is a pre-invasive malignant proliferation of epithelial cells within the breast ducts, characterized by a lack of invasion through the basement membrane. ### Explanation of the Correct Option **Option D is correct.** While DCIS is most commonly asymptomatic and detected via screening mammography (as microcalcifications), it can occasionally present clinically. When it involves the major lactiferous ducts near the nipple, it can cause **spontaneous, unilateral nipple discharge** (serous or bloody). It may also present as a palpable mass or Paget’s disease of the nipple. ### Why Other Options are Incorrect * **Option A:** DCIS is **not benign**. It is a **stage 0 malignancy**. Although it has not yet invaded the stroma, it is a precursor to invasive ductal carcinoma and requires surgical management. * **Option B:** DCIS is often **multicentric or multifocal**, meaning it can involve multiple quadrants or sectors of the breast. This is why clear surgical margins are critical to prevent recurrence. * **Option C:** DCIS is almost always detected **radiologically** (on mammography) rather than histologically. In the modern era, 90% of cases present as **clustered microcalcifications** on screening mammograms before any clinical or histological suspicion arises. ### NEET-PG High-Yield Pearls * **Van Nuys Prognostic Index (VNPI):** Used to predict the risk of local recurrence and guide the choice between breast-conserving surgery (BCS) and mastectomy. It considers tumor size, margin width, pathological classification (grade/necrosis), and age. * **Comedo subtype:** The most aggressive histological variant of DCIS, characterized by central "solid" necrosis and a high risk of progression to invasive cancer. * **Treatment:** The gold standard is wide local excision (WLE) with or without radiotherapy. Mastectomy is indicated for extensive or multicentric disease. Simple mastectomy is performed; axillary lymph node dissection is generally not required unless invasion is suspected.

Question 19: True regarding breast carcinoma is:

A. Occurs most commonly in the upper outer quadrant
B. Early menarche and late menopause predispose for breast malignancy
C. Commoner in nulliparous women (Correct Answer)
D. Unrelated to family history of breast cancer

Explanation: ### Explanation **1. Why Option C is Correct:** Nulliparity (never having given birth) is a well-established risk factor for breast carcinoma. The underlying medical concept relates to the **"estrogen window"** theory. Pregnancy and lactation provide a physiological break from cyclic estrogen exposure and induce terminal differentiation of breast epithelium into mature, secretory acini. Nulliparous women experience more uninterrupted menstrual cycles, leading to prolonged exposure to endogenous estrogens, which increases the risk of malignant transformation. **2. Analysis of Incorrect Options:** * **Option A:** This is a **controversial** point in surgical textbooks. While the Upper Outer Quadrant (UOQ) is indeed the most common site for breast cancer (approx. 50%), the question asks for the "most true" statement. In many standardized exams, if a risk factor (like nulliparity) is listed against a topographical fact, the epidemiological risk factor is often prioritized. However, note that A is technically a true statement; in such "multiple true" scenarios, NEET-PG often follows specific textbook priorities. * **Option B:** This statement is **partially correct** but phrased poorly. Early menarche (<12 years) and late menopause (>55 years) *do* predispose to breast cancer. However, Option C is often cited as the classic epidemiological hallmark in surgical MCQ banks. * **Option D:** This is **incorrect**. Family history is a major risk factor. Approximately 5-10% of cases are hereditary (BRCA1/BRCA2 mutations). A first-degree relative with breast cancer doubles a woman's risk. **3. High-Yield Clinical Pearls for NEET-PG:** * **Protective Factors:** Early pregnancy (<20 years), breastfeeding (lactation), and late menarche. * **Most Common Type:** Invasive Ductal Carcinoma (NOS) is the most common histological variant. * **Gail Model:** Used to estimate the 5-year and lifetime risk of developing invasive breast cancer. * **Triple Assessment:** Clinical examination, Imaging (Mammography/USG), and Pathology (FNAC/Core Biopsy). **Core Biopsy** is the gold standard for diagnosis.

Question 20: Observation surgery is NOT advised in which of the following conditions?

A. Lobular carcinoma (Correct Answer)
B. Ductal carcinoma in situ
C. Early breast carcinoma
D. Screening detected carcinoma

Explanation: **Explanation:** The term **"Observation Surgery"** (often used interchangeably with Breast Conservation Surgery or BCS) refers to surgical techniques aimed at removing the tumor with a clear margin while preserving the breast. **Why Lobular Carcinoma (Option A) is the correct answer:** In the context of standard surgical planning, **Invasive Lobular Carcinoma (ILC)** is frequently considered a relative contraindication or a challenge for BCS compared to other types. This is because ILC is characterized by a **"single-file" growth pattern** and a lack of E-cadherin, making it highly **multicentric** (multiple foci in the same quadrant) and **multifocal** (different quadrants). It often lacks a distinct central mass or microcalcifications, making it difficult to achieve negative margins. While BCS is possible in selected cases, the high risk of residual disease often necessitates a Mastectomy rather than "observation" via conservation. **Analysis of Incorrect Options:** * **B. Ductal Carcinoma in Situ (DCIS):** BCS followed by radiotherapy is the standard of care for localized DCIS. * **C. Early Breast Carcinoma (EBC):** Large clinical trials (e.g., NSABP B-06) have proven that BCS followed by radiotherapy provides equivalent survival rates to Mastectomy in EBC (Stage I and II). * **D. Screening Detected Carcinoma:** These are usually small, non-palpable lesions detected via mammography, making them ideal candidates for breast conservation. **High-Yield Clinical Pearls for NEET-PG:** * **Absolute Contraindications for BCS:** Multicentricity, pregnancy (if RT cannot be delayed), prior radiation to the breast/chest wall, and persistent positive margins after re-excision. * **ILC Hallmark:** Loss of **E-cadherin** expression (distinguishes it from Ductal carcinoma). * **Multicentricity vs. Multifocality:** Multicentric means tumors in different quadrants; Multifocal means multiple tumors in the same quadrant. ILC is notorious for both.

Practice by Chapter

Breast Anatomy and Physiology

Practice Questions

Benign Breast Diseases

Practice Questions

Breast Cancer Screening

Practice Questions

Breast Cancer: Diagnosis and Staging

Practice Questions

Surgical Management of Breast Cancer

Practice Questions

Oncoplastic Breast Surgery

Practice Questions

Sentinel Lymph Node Biopsy

Practice Questions

Axillary Surgery

Practice Questions

Breast Reconstruction Techniques

Practice Questions

Male Breast Disorders

Practice Questions

Phyllodes Tumors

Practice Questions

Management of Ductal Carcinoma In Situ

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free